Evidence map›Paper›PMID 40074805›Full record

SynthesisEvidence-based dentistry2025

Osteopontin as a prognostic biomarker in head and neck cancer- a systematic review and meta-analysis.

Nadisha Piyarathne, Kalani Hettiarachchi, Monal Yuwanati, Gowri Sivaramakrishnan, Anand Ramanathan, Ruwan Jayasinghe, Sanaa Chala, Akhilanand Chaurasia

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Evidence-based dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nadisha PiyarathneDepartment of Basic Sciences, Center for Research in Oral Cancer (CROC), Faculty of Dental Sciences, University of Peradeniya, Peradeniya, Sri Lanka.ORCID http://orcid.org/0000-0001-5834-6854
Kalani HettiarachchiFrazer Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Monal YuwanatiDepartment of Oral and Maxillofacial pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, 600077, India.ORCID http://orcid.org/0000-0001-9233-8292
Gowri SivaramakrishnanBahrain Defence Force Royal medical services, Manama, Bahrain.ORCID http://orcid.org/0000-0002-5877-205X
Anand RamanathanDepartment of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
Ruwan JayasingheDepartment of Oral Medicine and Periodontology, Faculty of Dental Sciences, University of Peradeniya, Peradeniya, Sri Lanka.ORCID http://orcid.org/0000-0002-8054-4301
Sanaa ChalaFaculty of Dental Medicine, Mohammed V University in Rabat, Rue Mohammed Jazouli, BP, 6212 Madinat Al Irfane, Rabat, Morocco.ORCID http://orcid.org/0000-0002-6227-9364
Akhilanand ChaurasiaDepartment of Oral Medicine and Radiology, King George's Medical University, Lucknow, Uttar Pradesh, India. chaurasiaakhilanand49@gmail.com.ORCID http://orcid.org/0000-0002-8356-9512

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteopontin (OPN) is linked to cancer progression, metastasis, and treatment resistance in head and neck cancer (HNC). This meta-analysis evaluated OPN as a prognostic biomarker in HNC.

methodA comprehensive search was conducted for studies published up to December 2023, including English papers on HNC analyzing OPN expression. Data extraction, quality assessment, and quantitative analysis were performed using fixed and random effect models with 95% CI. Heterogeneity and publication bias were assessed with I2 and Egger's regression test.

resultsFifty-one studies were included. OPN expression was significantly elevated in tissue and plasma in HNC compared to control (SMD 0.98; 95% CI 0.47-1.49; I2 = 13%; p < 0.00). High plasma OPN predicted poor survival (HR: 2.00; I2 = 64%; P = 0.03), as did high tissue OPN (hazard ratio: 2.71, 95% confidence interval = 1.51-4.87; I2 = 49.4%, p > 0.05). Elevated plasma OPN correlated with smoking, poorly differentiated neoplasms, larger tumors, advanced stage, and lymph node metastasis. Positive tissue OPN was associated with nodal involvement, advanced stage, male gender, and smoking.

conclusionOPN is a robust prognostic biomarker in HNC, indicating tumor aggressiveness and poor prognostic outcomes. Standardized measurement protocols and further validation in prospective studies are necessary.

Indexed as

Biomarkers, TumorHead and Neck NeoplasmsOsteopontinHumansPrognosisBiomarkers, TumorOsteopontin

Identifiers

PMID40074805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.